Menu Search
Equities

MacroGenics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
M55:STU

MacroGenics Inc

Actions
  • Price (EUR)1.43
  • Today's Change-0.082 / -5.41%
  • Shares traded0.00
  • 1 Year change-37.42%
  • Beta1.4836
Data delayed at least 15 minutes, as of Feb 10 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its other product candidates are MGD024, retifanlimab, enoblituzumab, and vobramitamab duocarmazine. MGD024 is an investigational, next-generation, bispecific CD123 CD3 DART molecule designed to engage CD3 expressed on immune effector cells, such as T cells.

  • Revenue in USD (TTM)127.63m
  • Net income in USD-75.89m
  • Incorporated2000
  • Employees341.00
  • Location
    MacroGenics Inc9704 Medical Center DriveROCKVILLE 20850United StatesUSA
  • Phone+1 (301) 251-5172
  • Fax+1 (301) 251-5321
  • Websitehttps://www.macrogenics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.